PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Immix Biopharma, Inc. (IMMX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US45258H1068

CUSIP

45258H106

Sector

Healthcare

IPO Date

Dec 16, 2021

Highlights

Market Cap

$47.21M

EPS (TTM)

-$0.83

Total Revenue (TTM)

$4.78K

Gross Profit (TTM)

-$46.44K

EBITDA (TTM)

-$15.67M

Year Range

$1.26 - $7.75

Target Price

$7.00

Short %

5.07%

Short Ratio

2.94

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
IMMX vs. VMNIX
Popular comparisons:
IMMX vs. VMNIX

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Immix Biopharma, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%10.00%JuneJulyAugustSeptemberOctoberNovember
-32.54%
11.08%
IMMX (Immix Biopharma, Inc.)
Benchmark (^GSPC)

Returns By Period

Immix Biopharma, Inc. had a return of -75.43% year-to-date (YTD) and -61.01% in the last 12 months.


IMMX

YTD

-75.43%

1M

-1.16%

6M

-31.17%

1Y

-61.01%

5Y (annualized)

N/A

10Y (annualized)

N/A

^GSPC (Benchmark)

YTD

23.62%

1M

0.54%

6M

11.19%

1Y

30.63%

5Y (annualized)

13.61%

10Y (annualized)

11.16%

Monthly Returns

The table below presents the monthly returns of IMMX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-44.80%-12.30%-8.36%-29.32%-2.76%-6.16%4.55%3.38%-30.37%7.38%-75.43%
202313.54%-20.00%-12.50%35.71%-18.22%33.17%-23.42%-1.46%68.47%5.85%41.16%35.42%202.18%
202214.04%-26.60%-19.13%-42.74%55.07%21.50%-6.15%-25.41%-25.27%-26.47%21.00%89.26%-35.67%
2021-3.00%-3.00%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of IMMX is 14, indicating that it is in the bottom 14% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of IMMX is 1414
Combined Rank
The Sharpe Ratio Rank of IMMX is 1414
Sharpe Ratio Rank
The Sortino Ratio Rank of IMMX is 1414
Sortino Ratio Rank
The Omega Ratio Rank of IMMX is 1616
Omega Ratio Rank
The Calmar Ratio Rank of IMMX is 66
Calmar Ratio Rank
The Martin Ratio Rank of IMMX is 2222
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Immix Biopharma, Inc. (IMMX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for IMMX, currently valued at -0.61, compared to the broader market-4.00-2.000.002.004.00-0.612.51
The chart of Sortino ratio for IMMX, currently valued at -0.75, compared to the broader market-4.00-2.000.002.004.00-0.753.37
The chart of Omega ratio for IMMX, currently valued at 0.92, compared to the broader market0.501.001.502.000.921.47
The chart of Calmar ratio for IMMX, currently valued at -0.76, compared to the broader market0.002.004.006.00-0.763.63
The chart of Martin ratio for IMMX, currently valued at -0.98, compared to the broader market0.0010.0020.0030.00-0.9816.15
IMMX
^GSPC

The current Immix Biopharma, Inc. Sharpe ratio is -0.61. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Immix Biopharma, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.

Rolling 12-month Sharpe Ratio-1.000.001.002.003.00JuneJulyAugustSeptemberOctoberNovember
-0.61
2.51
IMMX (Immix Biopharma, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Immix Biopharma, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-80.00%-60.00%-40.00%-20.00%0.00%JuneJulyAugustSeptemberOctoberNovember
-76.62%
-1.75%
IMMX (Immix Biopharma, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Immix Biopharma, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Immix Biopharma, Inc. was 88.89%, occurring on Nov 10, 2022. Recovery took 275 trading sessions.

The current Immix Biopharma, Inc. drawdown is 76.62%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-88.89%Jan 6, 2022214Nov 10, 2022275Dec 15, 2023489
-81.57%Dec 18, 2023200Oct 3, 2024
-26.25%Dec 20, 20214Dec 23, 20216Jan 3, 202210

Volatility

Volatility Chart

The current Immix Biopharma, Inc. volatility is 20.72%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%JuneJulyAugustSeptemberOctoberNovember
20.72%
4.07%
IMMX (Immix Biopharma, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Immix Biopharma, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Immix Biopharma, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items